ATE373089T1 - Mutationen in ionenkanälen - Google Patents

Mutationen in ionenkanälen

Info

Publication number
ATE373089T1
ATE373089T1 AT02748429T AT02748429T ATE373089T1 AT E373089 T1 ATE373089 T1 AT E373089T1 AT 02748429 T AT02748429 T AT 02748429T AT 02748429 T AT02748429 T AT 02748429T AT E373089 T1 ATE373089 T1 AT E373089T1
Authority
AT
Austria
Prior art keywords
subject
mutations
ion channels
ion channel
undergone
Prior art date
Application number
AT02748429T
Other languages
English (en)
Inventor
John Mulley
Louise Harkin
Leanne Dibbens
Hilary Phillips
Sarah Heron
Samuel Berkovic
Ingrid Scheffer
Robyn Wallace
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR6452A external-priority patent/AUPR645201A0/en
Priority claimed from AUPS0910A external-priority patent/AUPS091002A0/en
Priority claimed from AUPS2292A external-priority patent/AUPS229202A0/en
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Application granted granted Critical
Publication of ATE373089T1 publication Critical patent/ATE373089T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
AT02748429T 2001-07-18 2002-07-08 Mutationen in ionenkanälen ATE373089T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR6452A AUPR645201A0 (en) 2001-07-18 2001-07-18 Mutations in ion channels
AUPS0910A AUPS091002A0 (en) 2002-03-05 2002-03-05 Mutations in ion channels
AUPS2292A AUPS229202A0 (en) 2002-05-13 2002-05-13 Novel mutations

Publications (1)

Publication Number Publication Date
ATE373089T1 true ATE373089T1 (de) 2007-09-15

Family

ID=27158306

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02748429T ATE373089T1 (de) 2001-07-18 2002-07-08 Mutationen in ionenkanälen

Country Status (9)

Country Link
US (2) US20050074764A1 (de)
EP (2) EP1852505B1 (de)
JP (1) JP2005501536A (de)
AT (1) ATE373089T1 (de)
AU (1) AU2002318972B8 (de)
CA (1) CA2454073C (de)
DE (1) DE60222422D1 (de)
NZ (2) NZ530258A (de)
WO (1) WO2003008574A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE373089T1 (de) 2001-07-18 2007-09-15 Bionomics Ltd Mutationen in ionenkanälen
AU2003904154A0 (en) * 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
US7709225B2 (en) * 2001-07-18 2010-05-04 Bionomics Limited Nucleic acids encoding mutations in sodium channels related to epilepsy
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
AU2003901425A0 (en) * 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
AU2004263548B2 (en) * 2003-08-07 2007-09-13 Bionomics Limited Mutations in ion channels
WO2005035784A1 (en) * 2003-10-13 2005-04-21 Bionomics Limited A diagnostic method for neonatal or infantile epilepsy syndromes
US20070249518A1 (en) * 2004-12-24 2007-10-25 Ares Trading S.A. Compositions and Methods for Treating Mental Disorders
NZ564892A (en) * 2005-06-16 2011-10-28 Bionomics Ltd Methods of treatment, and diagnosis of epilepsy by detecting a D674G mutation in the SCN1A gene
US20100311610A1 (en) * 2008-02-01 2010-12-09 Chromocell Corporation CELL LINES AND METHODS FOR MAKING AND USING THEM (As Amended)
EP2770325A1 (de) 2013-02-26 2014-08-27 Institut du Cerveau et de la Moelle Epiniere-ICM Mutationen von DEPDC5 zur Diagnose von epileptischen Funktionsstörungen, Erkrankungen oder Leiden
EP3744346A4 (de) 2018-01-26 2022-04-20 National University Corporation Tokai National Higher Education and Research System Gegen rezeptorprotein gerichtetes therapeutikum, prüfstoff, an rezeptorprotein bindender antikörper und screening-verfahren für molukular anvisierte wirkstoffe

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4971903A (en) * 1988-03-25 1990-11-20 Edward Hyman Pyrophosphate-based method and apparatus for sequencing nucleic acids
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
NO175199C (no) 1991-12-05 1994-09-14 Kvaerner Fjellstrand As Flerskrogfartöy
AU701228B2 (en) * 1995-06-28 1999-01-21 University Of Bonn Diagnostic and treatment methods relating to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)
US5646040A (en) 1995-06-30 1997-07-08 Millennium Pharmaceutical, Inc. Mammalian tub gene
US6331614B1 (en) * 1998-12-23 2001-12-18 Myriad Genetics, Inc. Human CDC14A gene
WO2001038564A2 (en) * 1999-11-26 2001-05-31 Mcgill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
US6703439B2 (en) * 2000-02-09 2004-03-09 Mitsui Chemicals, Inc. Polyolefin resin composition and polyolefin film prepared from the same
AUPQ749100A0 (en) 2000-05-12 2000-06-08 Bionomics Limited New epilespy gene
CA2411756A1 (en) 2000-06-20 2001-12-27 Bionomics Limited Mutation associated with epilepsy
AUPQ882600A0 (en) 2000-07-18 2000-08-10 Bionomics Limited Mutations in ion channels
US6661614B2 (en) * 2000-09-27 2003-12-09 Seagate Technology Llc Magnetless actuator for disc drive
AUPR220300A0 (en) 2000-12-20 2001-01-25 Bionomics Limited New epilepsy gene
AUPR492201A0 (en) 2001-05-10 2001-06-07 Bionomics Limited Novel mutation
US7709225B2 (en) * 2001-07-18 2010-05-04 Bionomics Limited Nucleic acids encoding mutations in sodium channels related to epilepsy
AU2003904154A0 (en) 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
US7282336B2 (en) * 2001-07-18 2007-10-16 Bionomics Limited Method of diagnosing epilepsy
ATE373089T1 (de) 2001-07-18 2007-09-15 Bionomics Ltd Mutationen in ionenkanälen
EP1474176A4 (de) * 2001-11-26 2005-06-15 Bristol Myers Squibb Co Neuer menschlicher g-protein-gekoppelter rezeptor hgprbmy31 sowie varianten davon und verwendungsverfahren dafür
AU2003901425A0 (en) 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
NZ564892A (en) * 2005-06-16 2011-10-28 Bionomics Ltd Methods of treatment, and diagnosis of epilepsy by detecting a D674G mutation in the SCN1A gene

Also Published As

Publication number Publication date
EP1852505A1 (de) 2007-11-07
WO2003008574A1 (en) 2003-01-30
AU2002318972B8 (en) 2007-08-09
JP2005501536A (ja) 2005-01-20
NZ530258A (en) 2006-01-27
AU2002318972B2 (en) 2007-03-08
EP1407013B1 (de) 2007-09-12
US20050074764A1 (en) 2005-04-07
AU2002318972A1 (en) 2003-03-03
EP1852505B1 (de) 2010-03-31
CA2454073A1 (en) 2003-01-30
NZ542048A (en) 2008-04-30
CA2454073C (en) 2012-08-28
EP1407013A4 (de) 2005-06-22
US20100136623A1 (en) 2010-06-03
US7989182B2 (en) 2011-08-02
DE60222422D1 (de) 2007-10-25
EP1407013A1 (de) 2004-04-14

Similar Documents

Publication Publication Date Title
ATE373089T1 (de) Mutationen in ionenkanälen
ZA200703433B (en) Identification of a JAK2 mutation in polycythemia vera
TW200631594A (en) Toll like receptor 3 antagonists, methods and uses
TWI365610B (en) Systems and methods for scalably encoding and decoding data
SI2185686T1 (sl) Dendritične celice
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
EP1053253A4 (de) Neue dns-sequenzen, die für einen gaba b-rezeptor kodieren.
ATE412751T1 (de) Menschliche tak1 und für diese kodierende dna
ATE340451T1 (de) Netzwerkgerät, system und verfahren zur authentifizierung
EE200100234A (et) PRV-1-geen ja selle kasutamine
ATE318933T1 (de) Nukleinsäurefragmente zur identifizierung von dechlorierenden bakterien
DK1196607T3 (da) Antibakterielt chlamysin B-protein, gen kodende derfor samt ekspressionssystem
DE60329931D1 (de) Fprl1-liganden und deren verwendung
WO2006046994A3 (en) Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk
ATE320496T1 (de) Testisspezifische, menschliche proteinase, svph1- 8
DK1470228T3 (da) Detektion af mutationer
高虎 Sd. Kfz. 251/1 Ausf. D Sd. Kfz. 251/7 Ausf. D
ATE517181T1 (de) Rekombinante carboxypeptidase b
ATE408686T1 (de) Chondrosarcom-assoziierte gene
DK1716237T3 (da) Orotat-transportørkodende markørgener
WO2003025225A3 (en) Pthr1 gene polymorphisms
UY27053A1 (es) Polimorfismos de nucleótidos simples humanos
Driscoll et al. Response from driscoll and colleagues
WO2005031341A3 (en) Methods for predicting development of insulin resistance
DE60135971D1 (de) Mit wt1 interagierendes protein, wtip

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties